KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
Zipalertinib + Chemotherapy Extends PFS by 6 Months in Frontline EGFR Exon 20 Insertion–Positive NSCLC
2
FDA Grants Breakthrough Therapy Designation to First-Line Daraxonrasib Plus Chemo in mPDAC
3
Updated NCCN Guidelines Feature Additional MRD Recommendations in Multiple Myeloma
4
FDA Clears sNDA for Taletrectinib With Updated DOR Data in ROS1+ NSCLC
5